New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared ...
CBX-12 is under clinical development by Cybrexa and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...
Researchers at IIT Guwahati and Bose Institute Kolkata have developed an innovative injectable hydrogel for targeted breast cancer therapy. This breakthrough enables precise drug delivery to tumours, ...
cuet pg syllabus 2024 New targeted therapy for cancer treatment! How much do you know about peptide-drug conjugates (PDC)? Novartis/Genentech's Xolair gets FDA approval for new indication To ...